my.chemeurope.com
With an accout for my.chemeurope.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
30-11-2005: Z-Cube, the corporate venture capital arm of the Zambon Group took another important step forwards in fostering pharmaceutical innovation, signing a contract to provide finance and expert support to SuppreMol GmbH. This marked the project's official launch as a new company after several years of basic research and proof of principle of a new therapeutic approach in autoimmune diseases. SuppreMol is a spin-off company of the Max-Planck-Institute of Biochemistry in Munich, Germany set up with the support of Garching Innovation GmbH, the technology transfer office of the Max Planck Society.
SuppreMol is working on the development of drugs for the treatment of autoimmune diseases and allergies through innovative therapeutic approaches centred on Fc -receptors. The development of these drugs is based on patent rights owned by the Max-Planck-Society and licensed to SuppreMol by the Society's Technology Transfer office, Garching Innovation. SuppreMol's principal objective is to prove the therapeutic efficacy of a soluble Fc receptor in the treatment of Idiopathic Thrombocytopenic Purpura, Systemic Lupus Erythematosus, Rheumatoid Arthritis and other autoimmune diseases.
Watchlist
This is where you can add this news to your personal favourites
Chaperones for climate protection
The World Climate Conference recently took place. Reports about carbon dioxide levels, rising temperatures and melting glaciers appear daily. Scientists from the Max Planck Institute (MPI) of Biochemistry and the Gene Center of Ludwig Maximilians University Munich have now succeeded in rebu ... more
SuppreMol launched as a new company
Z-Cube, the corporate venture capital arm of the Zambon Group took another important step forwards in fostering pharmaceutical innovation, signing a contract to provide finance and expert support to SuppreMol GmbH. This marked the project's official launch as a new company after several yea ... more
Software for the discovery of new crystal structures
A new software called QED (Quantitative Electron Diffraction), which has been licensed by Max Planck Innovation, has now been released by HREM Research Inc., a Japan based company, which is developing products and services in the field of High-Resolution Electron Microscopy. QED allows tran ... more
Max Planck Innovation grants rights for developing new nanoscopic method to Leica Microsystems
Max Planck Innovation, the technology transfer organization of the Max Planck Society, grants Leica Microsystems, Wetzlar, an exclusive license for implementing the latest generation of optical microscopes with a resolution far below the diffraction limit (nanoscopes). This innovative optic ... more
Max Planck Innovation GmbH has signed an exclusive license agreement with BWT subsidiary FuMA-Tech GmbH for a patent covering a novel material for fuel cell membranes, its synthesis and use. The novel material, sulfonated poly(arylene) bears the potential to overcome some of the limitation ... more
Über CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2013 CHEMIE.DE Information Service GmbH, All rights reserved
Netmeeting
